$TECH (BIO-TECHNE) — 8-K: Bio-Techne Q4 revenue hits $321.2M as Merck KGaA acquisition advances

Fourth quarter revenue rose 1% to $321.2 million, with organic growth of 3%. GAAP EPS was $0.35, up from a loss of $0.11 a year ago, while adjusted EPS was $0.52 compared to $0.53. Full-year revenue remained flat at $1.2 billion, with GAAP EPS of $1.16 and adjusted EPS of $1.93. The pending acquisition by Merck KGaA for $73 per share in cash values the company at approximately $11.3 billion.

Fourth quarter revenue rose 1% to $321.2 million, with organic growth of 3%. GAAP EPS was $0.35, up from a loss of $0.11 a year ago, while adjusted EPS was $0.52 compared to $0.53. Full-year revenue remained flat at $1.2 billion, with GAAP EPS of $1.16 and adjusted EPS of $1.93. The pending acquisition by Merck KGaA for $73 per share in cash values the company at approximately $11.3 billion.